Niagen Bioscience director granted 31,746 stock options
Niagen Bioscience director Frank L. Jaksch Jr. received a compensation-related stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Niagen Bioscience director Frank L. Jaksch Jr. received a compensation-related stock option grant. He was awarded options to acquire 31,746 shares of Common Stock at an exercise price of $3.45 per share. The option vests 100% on June 24, 2027 and expires on June 23, 2036. Following this grant, he holds 31,746 derivative securities directly, with no open-market buying or selling reported in this filing.
Insider Trade Summary
Grant/Award: 31,746 shares
Grant/Award
1 txn
Insider
Jaksch Frank L Jr
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 31,746 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 31,746 contracts (Direct)
Footnotes (1)
- F1. Option vests 100% on June 24, 2027.
Key Figures
Options granted: 31,746 options
Exercise price: $3.45 per share
Underlying shares: 31,746 shares
+3 more
6 metrics
Options granted
31,746 options
Stock Option grant to director on June 24, 2026
Exercise price
$3.45 per share
Conversion/exercise price of stock option
Underlying shares
31,746 shares
Common Stock underlying the option award
Vesting date
June 24, 2027
Option vests 100% on this date
Expiration date
June 23, 2036
Final expiration of the stock option
Post-transaction derivatives
31,746 derivative securities
Total derivative holdings following transaction
Key Terms
Stock Option (right to buy), derivative securities, exercise price, vests 100%, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
derivative securities financial
"total_shares_following_transaction: 31,746.0000 derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price: 3.4500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests 100% financial
"Option vests 100% on June 24, 2027."
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Niagen Bioscience (NAGE) director Frank L. Jaksch Jr. report in this Form 4?
Frank L. Jaksch Jr. reported receiving a stock option grant. The award covers 31,746 shares of Common Stock, reflecting a compensation-related acquisition rather than an open-market stock purchase or sale.
How many Niagen Bioscience (NAGE) options were granted to Frank L. Jaksch Jr.?
He was granted options covering 31,746 shares of Niagen Bioscience Common Stock. These derivative securities give him the right to buy shares at a set price if he exercises the options in the future.
What is the exercise price of the Niagen Bioscience (NAGE) options granted?
The options have an exercise price of $3.45 per share. This means Jaksch can purchase Niagen Bioscience Common Stock at $3.45 per share once the options vest and before they expire.
When do Frank L. Jaksch Jr.’s Niagen Bioscience (NAGE) options vest and expire?
The option grant vests 100% on June 24, 2027. It expires on June 23, 2036, giving a multi-year window after vesting for potential exercise of these options.
Does this Niagen Bioscience (NAGE) Form 4 show any open-market buying or selling?
No open-market buying or selling is reported. The Form 4 only shows a grant of stock options as compensation, with no purchases or sales of Common Stock in the market.
How many derivative securities does Frank L. Jaksch Jr. hold after this Niagen Bioscience (NAGE) transaction?
After the transaction, he holds 31,746 derivative securities. This total reflects the newly granted stock options, with no additional derivative positions listed in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates